These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prostate cancer vaccines: current status. Hwang LC; Fein S; Levitsky H; Nelson WG Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730 [TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy for prostate cancer. Markiewicz MA; Kast WM Adv Cancer Res; 2003; 87():159-94. PubMed ID: 12641276 [TBL] [Abstract][Full Text] [Related]
8. Target antigens for prostate cancer immunotherapy. Saffran DC; Reiter RE; Jakobovits A; Witte ON Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787 [TBL] [Abstract][Full Text] [Related]
9. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cereda V; Poole DJ; Palena C; Das S; Bera TK; Remondo C; Gulley JL; Arlen PM; Yokokawa J; Pastan I; Schlom J; Tsang KY Cancer Immunol Immunother; 2010 Jan; 59(1):63-71. PubMed ID: 19495750 [TBL] [Abstract][Full Text] [Related]
10. Emerging role of immunotherapy in the management of prostate cancer. Slovin SF Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancer: advances in immunotherapy. Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491 [TBL] [Abstract][Full Text] [Related]
12. Standard treatments induce antigen-specific immune responses in prostate cancer. Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294 [TBL] [Abstract][Full Text] [Related]
13. Development of dendritic-cell based prostate cancer vaccine. Tjoa BA; Murphy GP Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633 [TBL] [Abstract][Full Text] [Related]
14. Current immunotherapeutic strategies in prostate cancer. Grosso JF; Drake CG Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549 [TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. Yu YD; Kim TJ Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664 [TBL] [Abstract][Full Text] [Related]
16. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443 [TBL] [Abstract][Full Text] [Related]
18. Immunology and immunotherapy approaches for prostate cancer. Elkord E Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764 [TBL] [Abstract][Full Text] [Related]
19. Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. Hadaschik B; Su Y; Huter E; Ge Y; Hohenfellner M; Beckhove P J Urol; 2012 Apr; 187(4):1458-65. PubMed ID: 22341271 [TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]